«Дарниця» пройшла інспектування та підтвердила відповідність вимогам GMP

Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account…

Pharmaceutical company 'Darnytsia' with the support of consulting company BPI Group conducted training for manufacturing enterprises. During the training, held at its own production facilities, Darnytsia’s specialists talked about the…